HRP20120144T4 - Terapijske uporabe spojeva koji imaju i sert i 5-ht3 i 5-ht1a aktivnost - Google Patents

Terapijske uporabe spojeva koji imaju i sert i 5-ht3 i 5-ht1a aktivnost Download PDF

Info

Publication number
HRP20120144T4
HRP20120144T4 HRP20120144TT HRP20120144T HRP20120144T4 HR P20120144 T4 HRP20120144 T4 HR P20120144T4 HR P20120144T T HRP20120144T T HR P20120144TT HR P20120144 T HRP20120144 T HR P20120144T HR P20120144 T4 HRP20120144 T4 HR P20120144T4
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
disease
compounds
therapeutic uses
dimethylphenylsulfanyl
Prior art date
Application number
HRP20120144TT
Other languages
English (en)
Inventor
Nicholas Moore
Marianne Dragheim
Aneil Batra
Jin Chon
Original Assignee
H. Lundbeck A/S
Takeda Pharmaceuticals U.S.A., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120144(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S, Takeda Pharmaceuticals U.S.A., Inc. filed Critical H. Lundbeck A/S
Publication of HRP20120144T1 publication Critical patent/HRP20120144T1/hr
Publication of HRP20120144T4 publication Critical patent/HRP20120144T4/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (4)

1. Uporaba 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina i njegovih farmaceutski prihvatljivih soli u proizvodnji 5 lijeka za liječenje bolesti izabrane između depresije, anksioznosti, ovisnosti ili kronične boli, pri čemu je taj lijek namijenjen uporabi kod bolesnika koji je prethodno liječen drugim lijekom za tu bolest, a čija je primjena prestala ili je smanjena zbog nuspojave povezane s poremećajem spavanja.
2. Uporaba prema zahtjevu 1, pri čemu je farmaceutski prihvatljiva sol bromovodična sol.
3. 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazin i njegove farmaceutski prihvatljive soli za uporabu u liječenju bolesti 10 izabrane između depresije, anksioznosti, ovisnosti ili kronične boli, pri čemu je navedeni lijek namijenjen uporabi kod bolesnika koji je prethodno liječen drugim lijekom za tu bolest, a čija je primjena prestala ili je smanjena zbog nuspojave povezane s poremećajem spavanja.
4. 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazin i farmaceutski prihvatljive soli za uporabu prema zahtjevu 3, pri čemu je to bromovodična sol.
HRP20120144TT 2007-11-13 2012-02-14 Terapijske uporabe spojeva koji imaju i sert i 5-ht3 i 5-ht1a aktivnost HRP20120144T4 (hr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US98771007P 2007-11-13 2007-11-13
DKPA200701607 2007-11-13
US1372207P 2007-12-14 2007-12-14
DKPA200701788 2007-12-14
US9784008P 2008-09-17 2008-09-17
DKPA200801300 2008-09-17
PCT/DK2008/050271 WO2009062517A1 (en) 2007-11-13 2008-11-12 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
EP08850935.1A EP2219647B2 (en) 2007-11-13 2008-11-12 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Publications (2)

Publication Number Publication Date
HRP20120144T1 HRP20120144T1 (hr) 2012-04-30
HRP20120144T4 true HRP20120144T4 (hr) 2020-11-13

Family

ID=40170671

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20120144TT HRP20120144T4 (hr) 2007-11-13 2012-02-14 Terapijske uporabe spojeva koji imaju i sert i 5-ht3 i 5-ht1a aktivnost
HRP20161121TT HRP20161121T1 (hr) 2007-11-13 2016-09-01 Terapijska uporaba spojeva koji imaju objedinjenu sert, 5-ht3 i 5-ht1a aktivnost

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20161121TT HRP20161121T1 (hr) 2007-11-13 2016-09-01 Terapijska uporaba spojeva koji imaju objedinjenu sert, 5-ht3 i 5-ht1a aktivnost

Country Status (30)

Country Link
US (5) US9278096B2 (hr)
EP (3) EP2431039B1 (hr)
JP (2) JP5603244B2 (hr)
KR (1) KR101536023B1 (hr)
CN (1) CN102014908A (hr)
AR (1) AR069260A1 (hr)
AT (1) ATE537829T1 (hr)
AU (1) AU2008323390B2 (hr)
BR (1) BRPI0820474B8 (hr)
CA (1) CA2705163C (hr)
CL (1) CL2008003363A1 (hr)
CO (1) CO6270322A2 (hr)
CY (2) CY1112646T1 (hr)
DK (2) DK2431039T3 (hr)
EA (1) EA027783B1 (hr)
ES (2) ES2591110T3 (hr)
HR (2) HRP20120144T4 (hr)
HU (1) HUE029588T2 (hr)
IL (1) IL205466A (hr)
LT (1) LT2431039T (hr)
MX (1) MX2010004688A (hr)
NZ (1) NZ585247A (hr)
PL (2) PL2431039T3 (hr)
PT (2) PT2431039T (hr)
RS (2) RS52256B2 (hr)
SG (1) SG10201405001XA (hr)
SI (2) SI2431039T1 (hr)
TW (1) TW200932233A (hr)
WO (1) WO2009062517A1 (hr)
ZA (1) ZA201003350B (hr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
CN102639117A (zh) 2009-08-24 2012-08-15 H.隆德贝克有限公司 1-[2-(2,4-二甲基-苯基硫基)-苯基]哌嗪的新组合物
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
AU2012209466C1 (en) * 2011-01-27 2016-06-23 Neuren Pharmaceuticals Limited Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid
JP6078466B2 (ja) 2011-07-21 2017-02-08 学校法人 名城大学 セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット
CN104853755B (zh) 2012-12-13 2017-08-22 H.隆德贝克有限公司 包含沃替西汀和多奈哌齐的组合物
JP6323979B2 (ja) * 2013-01-17 2018-05-16 学校法人 名城大学 うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
CN105339361A (zh) * 2013-05-31 2016-02-17 斯洛文尼亚莱柯制药股份有限公司 用于合成1-(2-((2，4-二甲基苯基)硫代)苯基)哌嗪的新方法
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
EP3082815B1 (en) * 2013-12-20 2018-10-03 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN106103418A (zh) 2014-01-31 2016-11-09 埃吉斯药物私人有限公司 沃替西汀盐的制备方法
EP2930171A1 (en) * 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
EP3799873A1 (en) * 2015-07-17 2021-04-07 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
KR20190025556A (ko) 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko) 2022-04-18 2023-10-25 영진약품 주식회사 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US5258387A (en) * 1990-08-21 1993-11-02 Hoffmann-La Roche Inc. Tricyclic pyridone derivatives
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CN100457738C (zh) * 2001-12-20 2009-02-04 H·隆德贝克有限公司 芳氧基苯基和芳硫基苯基衍生物
AU2004226838B8 (en) 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
US20060019938A1 (en) 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
PL2044043T5 (pl) 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
CN102639117A (zh) 2009-08-24 2012-08-15 H.隆德贝克有限公司 1-[2-(2,4-二甲基-苯基硫基)-苯基]哌嗪的新组合物

Also Published As

Publication number Publication date
ES2379419T3 (es) 2012-04-25
AR069260A1 (es) 2010-01-06
PT2219647E (pt) 2012-03-16
NZ585247A (en) 2012-03-30
CL2008003363A1 (es) 2009-06-05
DK2219647T4 (da) 2020-09-28
EP2219647B1 (en) 2011-12-21
RS55147B1 (sr) 2016-12-30
US20110201617A1 (en) 2011-08-18
PL2219647T3 (pl) 2012-07-31
EP2431039B1 (en) 2016-07-20
CA2705163A1 (en) 2009-05-22
EA201070598A1 (ru) 2010-10-29
CY1112646T1 (el) 2016-02-10
PL2431039T3 (pl) 2016-12-30
BRPI0820474A2 (pt) 2017-05-23
KR101536023B9 (ko) 2023-03-29
LT2431039T (lt) 2016-10-10
SI2219647T2 (sl) 2020-11-30
HRP20161121T1 (hr) 2017-01-27
BRPI0820474B8 (pt) 2021-05-25
US9278096B2 (en) 2016-03-08
CA2705163C (en) 2013-02-12
RS52256B (en) 2012-10-31
JP2011503125A (ja) 2011-01-27
ES2591110T3 (es) 2016-11-24
MX2010004688A (es) 2010-09-09
HUE029588T2 (en) 2017-03-28
TW200932233A (en) 2009-08-01
BRPI0820474B1 (pt) 2020-08-04
KR101536023B1 (ko) 2015-07-10
DK2219647T3 (da) 2012-03-19
HRP20120144T1 (hr) 2012-04-30
EP3115050A1 (en) 2017-01-11
IL205466A (en) 2014-06-30
RS52256B2 (sr) 2020-11-30
JP2014193891A (ja) 2014-10-09
PT2431039T (pt) 2016-09-29
SG10201405001XA (en) 2014-10-30
DK2431039T3 (en) 2016-09-26
ZA201003350B (en) 2011-08-31
AU2008323390A1 (en) 2009-05-22
WO2009062517A1 (en) 2009-05-22
US20160228430A1 (en) 2016-08-11
JP5841636B2 (ja) 2016-01-13
CY1117978T1 (el) 2017-05-17
KR20100099115A (ko) 2010-09-10
AU2008323390B2 (en) 2013-10-24
ES2379419T5 (es) 2021-05-04
EP2219647A1 (en) 2010-08-25
SI2431039T1 (sl) 2017-01-31
EP2219647B2 (en) 2020-07-29
IL205466A0 (en) 2010-12-30
EP2431039A1 (en) 2012-03-21
JP5603244B2 (ja) 2014-10-08
US20180161321A1 (en) 2018-06-14
CN102014908A (zh) 2011-04-13
US20210093631A1 (en) 2021-04-01
CO6270322A2 (es) 2011-04-20
US20240082239A1 (en) 2024-03-14
US9744166B2 (en) 2017-08-29
ATE537829T1 (de) 2012-01-15
SI2219647T1 (sl) 2012-06-29
US11628166B2 (en) 2023-04-18
EA027783B1 (ru) 2017-09-29

Similar Documents

Publication Publication Date Title
HRP20120144T4 (hr) Terapijske uporabe spojeva koji imaju i sert i 5-ht3 i 5-ht1a aktivnost
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
JP2006501240A5 (hr)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PE20060257A1 (es) Composicion farmaceutica de flibanserina para el tratamiento de trastornos premestruales y otros trastornos sexuales femeninos
HRP20170608T1 (hr) Terapijske uporabe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
HRP20120798T1 (hr) Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva
HRP20120558T1 (hr) Kapa-selektivni antagonist opioidnih receptora
JP2004512328A5 (hr)
HRP20140880T1 (hr) Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina
HRP20200662T1 (hr) Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak
CO6220957A2 (es) 4-2-(4-metilfenilsulfanil-fenil piperidina con inhibicion combinada de recaptacion de serotonina y norepinefrina para el tratamiento del trastorno de deficit de atencion e hiperactividad melancolia depresion resistente al tratamiento o sintomas resid
CY1113566T1 (el) Καρβαμοϋλο-κυκλοεξανια για τη θεραπευτικη αγωγη της οξειας μανιας
BR112012002246A2 (pt) composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
HRP20161389T1 (hr) Derivati pantotenata namijenjeni liječenju neuroloških poremećaja
JP2014533272A5 (hr)
BR112014004339A2 (pt) suspensão oral
JP2013536206A5 (hr)
JP2014534229A5 (hr)
WO2006086978A3 (de) Verwendung deuterierter n-[2-(5-methoxy-1h-indol-3-yl)-ethyl]acetamide und deren pharmazeutisch verträglicher salze sowie diese verbindungen enthaltende arzneimittel
JP2009511450A5 (hr)
JP2012502105A5 (hr)